Aktuelle Therapie des Basalzellkarzinoms

Zusammenfassung

Das Basalzellkarzinom ist in den letzten Jahren in den Fokus der translationalen Forschung gerückt, da die Entdeckung eines wichtigen Signaltransduktionsweges, des sog. Hedgehog-Pathways, die Entwicklung einer neuartigen therapeutischen Intervention ermöglichte.

Im Folgenden werden die wesentlichen Grundlagen zum Basalzellkarzinom und dessen bisherige Therapieoptionen besprochen sowie das Therapiekonzept der Hedgehog-Inhibitoren dargestellt.

Abstract

In recent years Basal Cell Carcinoma came in the focus of translational research since the discovery of an important signal transduction pathway, known as the Hedgehog pathway, allowed the development of a novel therapeutic intervention.

In the following the essential basics of Basal Cell Carcinoma and its current treatment options are discussed and the concept of hedgehog inhibitor therapy is presented.

• Literatur

• 1 Garbe C. Epidemiologie des Hautkrebses. In: Garbe C, Dummer R, Kaufmann R, Tilgen W, Hrsg. Dermatologische Onkologie. Berlin: Springer; 1997: 40-56
• 2 Hauschild A, Breuninger H, Kaufmann R et al. Kurzleitlinie – Basalzellkarzinom der Haut (Update 2011). unveröffentlicht
• 3 Samarasinghe V, Madan V, Lear JT. Focus on Basal cell carcinoma. Journal of skin cancer 2011; 328615
• 4 Im Internet: http://www.skincancer.gov.au/internet/skincancer/publishing.nsf/Content/fact-2
• 5 Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. Krebs in Deutschland 2003 – 2004. Häufigkeiten und Trends. Berlin: Robert-Koch-Institut; 2008
• 6 Breuninger H, Sebastian G, Kortmann R et al. Deutsche Leitlinie. Basalzellkarzinom. In: Garbe C, Hrsg. Interdisziplinäre Leitlinien zur Diagnostik und Behandlung von Hauttumoren. Stuttgart: Thieme; 2005: 1-11
• 7 Youssef KK, van Keymeulen A, Lapouge G et al. Identification of the cell lineage at the origin of basal cell carcinoma. Nature cell biology 2010; 12: 299-305
• 8 Epstein Jr EH. Mommy – where do tumors come from?. The Journal of clinical investigation 2011; 121: 1681-1683
• 9 Dessinioti C, Antoniou C, Katsambas A et al. Basal cell carcinoma: What’s new under the sun. Photochemistry and photobiology 2010; 86: 481-491
• 10 Kricker A, Armstrong BK, English DR et al. Does intermittent sun exposure cause basal cell carcinoma? a case-control study in Western Australia.. International journal of cancer. Journal international du cancer 1995; 60: 489-494
• 11 Rosso S, Zanetti R, Martinez C et al. The multicentre south European study ‘Helios’. II. Different sun exposure patterns in the aetiology of basal cell and squamous cell carcinomas of the skin. British journal of cancer 1996; 73: 1447-1454
• 12 Telfer NR, Colver GB, Morton CA. Guidelines for the management of basal cell carcinoma. The British journal of dermatology 2008; 159: 35-48
• 13 Roewert-Huber J, Lange-Asschenfeldt B, Stockfleth E et al. Epidemiology and aetiology of basal cell carcinoma. The British journal of dermatology 2007; 157: 47-51
• 14 Madan V, Hoban P, Strange RC et al. Genetics and risk factors for basal cell carcinoma. The British journal of dermatology 2006; 154: 5-7
• 15 Johnson RL, Rothman AL, Xie J et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996; 272: 1668-1671
• 16 Reifenberger J, Wolter M, Knobbe CB et al. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. The British journal of dermatology 2005; 152: 43-51
• 17 Nusslein-Volhard C, Wieschaus E. Mutations affecting segment number and polarity in Drosophila. Nature 1980; 287: 795-801
• 18 Reifenberger J. Basal cell carcinoma. Molecular genetics and unusual clinical features. Hautarzt 2007; 58: 406-411
• 19 Cui R, Widlund HR, Feige E et al. Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell 2007; 128: 853-864
• 20 Ramachandran S, Fryer AA, Smith AG et al. Basal cell carcinomas: association of allelic variants with a high-risk subgroup of patients with the multiple presentation phenotype. Pharmacogenetics 2001; 11: 247-254
• 21 Walling HW, Fosko SW, Geraminejad PA et al. Aggressive basal cell arcinoma: presentation, pathogenesis, and management. Cancer metastasis reviews 2004; 23: 389-402
• 22 Welzel J, Ulrich M, Lange-Asschenfeldt S, Hohenleutner U. Konfokale Lasermikroskopie in der Dermatologie. Im Internet: http://www.awmf.org/uploads/tx_szleitlinien/013-076l_S1_Konfokale_Lasermikroskopie_2011-07_01.pdf
• 23 Nori S, Rius-Diaz F, Cuevas J et al. Sensitivity and specificity of reflectance-mode confocal microscopy for in vivo diagnosis of basal cell carcinoma. a multicenter study. Journal of the American Academy of Dermatology 2004; 51: 923-930
• 24 Goppner D, Leverkus M. Basal cell carcinoma – from the molecular understanding of the pathogenesis to targeted therapy of progressive disease. Journal of skin cancer 2011; 650258
• 25 Jacob A. Observations respecting an ulcer of peculiar character, which attacks the eyelids and other parts of the face. Dublin Hospital Representative 1824; 4: 232-239
• 26 Ting PT, Kasper R, Arlette JP. Metastatic basal cell carcinoma: report of two cases and literature review. Journal of cutaneous medicine and surgery 2005; 9: 10-15
• 27 Smeets NW, Krekels GA, Ostertag JU et al. Surgical excision vs Mohs’ micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial. Lancet 2004; 364: 1766-1772
• 28 Mohs F. Chemosurgery. A microscopically controlled method of cancer excision. Archives of Surgery 1941; 42: 279-295
• 29 Petres J, Rompel R. Mikrographische Chirurgie. In: Operative Dermatologie: Lehrbuch und Atlas. Berlin: Springer; 2006
• 30 Holzschuh J, Breuninger H. Eine histologische Aufarbeitungstechnik von Hauttumorexzisaten zur lückenlosen Schnittrandkontrolle. Pathologe 1996; 17: 127-129
• 31 Woerle B, Heckmann M, Konz B. Micrographic surgery of basal cell carcinomas of the head. Recent Results Cancer Res 2002; 160: 219-224
• 32 Loser C, Rompel R, Breuninger H et al. Microscopically controlled surgery (MCS). JDDG 2010; 8: 920-925
• 33 Hulyalkar R, Rakkhit T, Garcia-Zuazaga J. The role of radiation therapy in the management of skin cancers. Dermatologic clinics 2011; 29: 287-296
• 34 Dummer R. Epitheliale Neoplasien der Haut. Epidemiologie, klinisches Spektrum, heutige Therapieoptionen. Onkologie 2009; 2: 6-10
• 35 Avril MF, Auperin A, Margulis A et al. Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study.. British journal of cancer 1997; 76: 100-106
• 36 Petit JY, Avril MF, Margulis A et al. Evaluation of cosmetic results of a randomized trial comparing surgery and radiotherapy in the treatment of basal cell carcinoma of the face. Plastic and reconstructive surgery 2000; 105: 2544-2551
• 37 Kopf AW, Bart RS, Schrager D et al. Curettage-electrodesiccation treatment of basal cell carcinomas. Archives of dermatology 1977; 113: 439-443
• 38 Thissen MR, Nieman FH, Ideler AH et al. Cosmetic results of cryosurgery versus surgical excision for primary uncomplicated basal cell carcinomas of the head and neck. Dermatol Surg 2000; 26: 759-764
• 39 Morton CA, McKenna KE, Rhodes LE. Guidelines for topical photodynamic therapy: update. The British journal of dermatology 2008; 159: 1245-1266
• 40 Rhodes LE, de Rie M, Enstrom Y et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Archives of dermatology 2004; 140: 17-23
• 41 Basset-Seguin N, Ibbotson S, Emtestam L. Photodynamic therapy using Metvix is as efficacious as cryotherapy in BCC, with better cosmetic results. J Eur Acad Dermatol Venereol 2004; 18: 412
• 42 Gollnick H, Barona CG, Frank RG et al. Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe. EJD 2008; 18: 677-682
• 43 Keeler RJ, Binns W. Teratogenic compounds of Veratrum californicum (Durand). 3. Malformations of the veratramine-induced type from ingestion of plant or roots. Proc Soc Exp Biol Med 1967; 126: 452-454
• 44 Cooper MK, Porter JA, Young KE et al. Teratogen-mediated inhibition of target tissue response to Shh signaling. Science 1998; 280: 1603-1607
• 45 Sekulic A, Migden M, Oro A et al. A pivotal study evaluating efficacy and safety of the hedgehog pathway inhibitor (HPI) vismodegib (GDC-0449) in patients with locally advanced (la) or metastatic (m) basal cell carcinoma (BCC). Melanoma Res 2011; 21: 9
• 46 Im Internet: http://clinicaltrials.gov/ct2/show/NCT01367665
• 47 Dummer R, Rodon J, Tawbi H et al. Phase I study of the smoothened inhibitor LDE225 in patients with advanced solid tumours. Dose limiting toxicity an anti-tumour activity. Melanoma Res 2011; 21: e3-e4
• 48 Im Internet: http://clinicaltrials.gov/ct2/show/NCT01327053
• 49 Ulrich C, Jurgensen JS, Degen A et al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. The British journal of dermatology 2009; 161: 78-84
• 50 Pandeya N, Purdie DM, Green A et al. Repeated occurrence of basal cell carcinoma of the skin and multifailure survival analysis: follow-up data from the Nambour Skin Cancer Prevention Trial. American journal of epidemiology 2005; 161: 748-754
• 51 van der Pols JC, Williams GM, Pandeya N et al. Prolonged prevention of squamous cell carcinoma of the skin by regular sunscreen use. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research cosponsored by the American Society of Preventive Oncology 2006; 15: 2546-2548
• 52 Im Internet: http://clinicaltrials.gov/ct2/show/NCT00829192
• 53 Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nature reviews. Cancer 2008; 8: 743-754